
Cellavision Q2 2025 - Stable with Decent Growth

Redeye comments on Cellavision's first quarter 2025, which saw organic sales growth of 8%, with the highest growth in ASEA. We make limited changes to our forecast.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Cellavision Q2 2025 - Stable with Decent Growth